EGFR and esophageal cancer: Protein level of EGFR, phospho‐AKT, and phospho‐ERK were downregulated toward PU‐H71 or Tubastatin A treatment and to a large extent towards combination treatment of PU‐H71 and Tubastatin A. These data validated that targeting HSP90‐HDAC6 interplay was also feasible in esophageal cancer.